STATERA BIOPHARMA, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0007 USD | 0.00% |
|
0.00% | +16.67% |
| 2023 | Statera Biopharma, Inc. entered into a letter of intent to acquire Worksite Labs. | CI |
| 2023 | Statera Biopharma, Inc.(OTCPK:STAB) dropped from S&P TMI Index | CI |
Valuation
| Fiscal Period: December | 2021 |
|---|---|
| Capitalization 1 | 73.82 |
| Enterprise Value (EV) 1 | 88.1 |
| P/E ratio | -0.79 x |
| Yield | - |
| Capitalization / Revenue | 49,642,171 x |
| EV / Revenue | 59,246,379 x |
| EV / EBITDA | -2,843,602 x |
| EV / FCF | -8,699,064 x |
| FCF Yield | -0% |
| Price to Book | -52 x |
| Nbr of stocks (in thousands) | 32,096 |
| Reference price 2 | 2.300 |
| Announcement Date | 10/6/22 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|
| Net sales | - | - | - | 1.487 |
| EBITDA | - | - | -10.5 | -30.98 |
| EBIT 1 | -7.924 | -3.002 | -10.5 | -31.24 |
| Operating Margin | - | - | - | -2,100.68% |
| Earnings before Tax (EBT) 1 | -6.132 | -3.224 | -12.09 | -101.9 |
| Net income 1 | -6.132 | -3.224 | -12.09 | -101.9 |
| Net margin | - | - | - | -6,849.25% |
| EPS 2 | -0.3586 | -0.1644 | -0.5610 | -2.901 |
| Free Cash Flow | - | 1.605 | -4.63 | -10.13 |
| FCF margin | - | - | - | -681.07% |
| FCF Conversion (EBITDA) | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - |
| Dividend per Share | - | - | - | - |
| Announcement Date | 2/16/21 | 2/16/21 | 5/7/21 | 10/6/22 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|
| Net Debt 1 | 1.56 | 1.8 | 1.41 | 14.3 |
| Net Cash position 1 | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | -0.1342 x | -0.461 x |
| Free Cash Flow | - | 1.61 | -4.63 | -10.1 |
| ROE (net income / shareholders' equity) | - | 91.2% | 308% | 3,947% |
| ROA (Net income/ Total Assets) | - | -877% | -1,266% | -176% |
| Assets 1 | - | 0.3675 | 0.9555 | 57.92 |
| Book Value Per Share 2 | -0.1700 | -0.2100 | -0.1500 | -0.0400 |
| Cash Flow per Share 2 | 0 | 0 | 0.0200 | 0.0500 |
| Capex | - | - | 0.01 | 0.18 |
| Capex / Sales | - | - | - | 12.3% |
| Announcement Date | 2/16/21 | 2/16/21 | 5/7/21 | 10/6/22 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +16.67% | 50.81K | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- STAB Stock
- Financials Statera Biopharma, Inc.
